Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

PURPOSE: This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced solid tumors. It also examined exploratory predictive and pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Timothy A., Krebs, Matthew G., Postel-Vinay, Sophie, El-Khouiery, Anthony, Soria, Jean-Charles, Lopez, Juanita, Berges, Alienor, Cheung, S.Y. Amy, Irurzun-Arana, Itziar, Goldwin, Andrew, Felicetti, Brunella, Jones, Gemma N., Lau, Alan, Frewer, Paul, Pierce, Andrew J., Clack, Glen, Stephens, Christine, Smith, Simon A., Dean, Emma, Hollingsworth, Simon J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401487/
https://www.ncbi.nlm.nih.gov/pubmed/34301752
http://dx.doi.org/10.1158/1078-0432.CCR-21-1032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401487/
https://www.ncbi.nlm.nih.gov/pubmed/34301752
http://dx.doi.org/10.1158/1078-0432.CCR-21-1032

Ejemplares similares